Nova Eye Medical : ITrack™ Canaloplasty to be Featured at the 2023 American Glaucoma Society (AGS) Annual Meeting

iTrack™ Canaloplasty to be Featured at the 2023 American Glaucoma Society (AGS) Annual Meeting

California, USA, 3 March 2023 - Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary iTrack™ canaloplasty technology will be featured during the official scientific program of the 2023 American Glaucoma Society (AGS) Annual Meeting, taking place on March 2 - 5, 2023, in Austin, Texas.

A summary of the key poster presentations is included below:

David Lubeck, MD, Robert Noecker, MD

"Endothelial Cell Density and Loss Following Ab-Interno Canaloplasty in Patients with Mild-Moderate Glaucoma as Compared to Severe Glaucoma"

David Lubeck, MD, Keith Barton, MD; Nathan Kerr, MD; Iqbal Ahmed, MD

"Longitudinal Data Registry on the Role of Canaloplasty for Treatment of

Glaucoma"

Christian Berry, MD, Mahmoud A. Khaimi, MD, Norbert J. Koerber, MD, FEBO, Simon Ondrejka, MD, Mark J. Gallardo, MD

"Consistency in standalone Ab-Interno Canaloplasty (ABiC) outcomes"

Jessica Hsueh, MD, Mahmoud Khaimi, MD

"Ab-interno canaloplasty (ABiC) in primary angle closure glaucoma

spectrum"

Umar Sandhu, BA, Neal Rangu, BA, Mohsain Gill, MD, Kamran Riaz, MD, Mahmoud Khaimi, MD

"Performing Ab-Interno Canaloplasty Post Keratoplasty - 2 Years

Outcomes"

1

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™, a consumable surgical device for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

Canaloplasty is typically performed using either of the following two surgical techniques:

• Performed via an ab-interno surgical technique, canaloplasty is a highly effective treatment option for cases of mild-moderate glaucoma. It typically reduces intraocular pressure (IOP) to the low teens. It has also been observed to reduce patient dependence on medications. The ab- interno surgical technique is an implant-free,tissue-sparing procedure that preserves future treatment options.

2

• Performed via an ab-externo surgical technique, canaloplasty is a highly effective treatment option for patients with severe glaucoma that overcomes the risks and discomfort associated with traditional glaucoma surgery. With over 100,000 procedures performed to date, clinical studies show that canaloplasty has an excellent safety profile, with minimal post-operativefollow-up, fast recovery time, and infrequent intra-operative and postoperative complications.

ABOUT THE iTRACK™ PORTFOLIO

Nova Eye Medical (formerly iScience Interventional) pioneered the canaloplasty market with the launch of the world's first canaloplasty device, iTrack™, in 2008. Since then, more than 120,000 canaloplasty procedures have been performed with the iTrack™ canaloplasty device, cementing its role in the treatment of glaucoma both as a standalone procedure and in combination with cataract surgery.

The iTrack™ canaloplasty microcatheter has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open- angle glaucoma. The iTrack™ canaloplasty microcatheter is currently not 510(k) cleared for use with the ab-interno technique in the United States.

For additional information about iTrack™, including safety information, please visit: www.glaucoma-iTrack.com

3